| Name | Title | Contact Details |
|---|
Selena Group is a leading global manufacturer of construction chemicals and polyurethane foam, established in 1992 and based in Wrocław, Poland. The company operates in 18–19 countries with around 1,800–2,000 employees and has 30–35 subsidiaries, including manufacturing facilities in Poland, South Korea, China, Romania, Turkey, Spain, Kazakhstan, and Italy. Selena Group is recognized as one of the top four manufacturers of assembly foam and a significant distributor of construction chemicals. Its product range includes high-yield polyurethane foams, sealants, adhesives, waterproofing systems, and thermal insulation solutions. The company operates through four specialized divisions: Interior & Decorations, Windows & Doors, Waterproofing, and Walls, Facades & Chemical Constructions. Selena serves 100 markets worldwide, focusing on professional contractors, industrial users, and home builders, while emphasizing sustainability and innovation in its offerings.
Invio Automation is a prominent provider of custom automation solutions, focusing on designing, building, and integrating advanced systems for high-growth industries. The company serves sectors such as Medical Device & Life Sciences, Renewable Energy, Mobility, Logistics & Fulfillment, and Industrial. With over 65 years of experience, Invio is headquartered in Hudson, NH, and operates seven production sites across North America. The team at Invio consists of hundreds of engineers and skilled professionals dedicated to delivering large-scale automation projects. Their offerings include robotic automation services, development of Autonomous Mobile Robots (AMRs), and a range of specialized solutions such as thermal bonding and precision dispensing. Invio also provides consulting and R&D services to help clients prepare for future automation needs. The company collaborates with a diverse customer base, supporting operations of all sizes across various industries.
Giupedi Utilizes Generative AI for High Quality Legal Client Acquisition Giupedi has created a unique Platform for advertising and marketing in the Workers Compensation, Medical Malpractice, and Personal Injury litigation industry. Prospective clients are empowered to make decisions and attorney selections in a manner that utilizes Generative AI and Secure Information Sharing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.